Phenylalanyl-threonine
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Others |
| Catalog number | BBF-05422 |
| CAS | 51352-44-4 |
| Molecular Weight | 266.29 |
| Molecular Formula | C13H18N2O4 |
| Purity | ≥98% |
Online Inquiry
Description
Phenylalanyl-threonine is a dipeptide composed of phenylalanine and threonine. It is an incomplete breakdown product of protein digestion or protein catabolism.
Specification
| Synonyms | L-Threonine, L-phenylalanyl-; Phe-Thr; H-FT-OH; L-Phe-L-Thr; L-phenylalanyl-L-threonine |
| Sequence | H-Phe-Thr-OH |
| IUPAC Name | (2S,3R)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-hydroxybutanoic acid |
| Canonical SMILES | CC(C(C(=O)O)NC(=O)C(CC1=CC=CC=C1)N)O |
| InChI | InChI=1S/C13H18N2O4/c1-8(16)11(13(18)19)15-12(17)10(14)7-9-5-3-2-4-6-9/h2-6,8,10-11,16H,7,14H2,1H3,(H,15,17)(H,18,19)/t8-,10+,11+/m1/s1 |
| InChI Key | NYQBYASWHVRESG-MIMYLULJSA-N |
Properties
| Appearance | Solid |
| Boiling Point | 563.5±50.0°C (Predicted) |
| Melting Point | 127-128°C |
| Density | 1.282±0.06 g/cm3 (Predicted) |
| Solubility | Soluble in Water |
Reference Reading
1. A joint analysis of metabolomic profiles associated with muscle mass and strength in Caucasian women
Qi Zhao, Hui Shen, Kuan-Jui Su, Qing Tian, Lan-Juan Zhao, Chuan Qiu, Timothy J Garrett, Jiawang Liu, David Kakhniashvili, Hong-Wen Deng Aging (Albany NY). 2018 Oct 14;10(10):2624-2635. doi: 10.18632/aging.101574.
Both loss of muscle mass and strength are important sarcopenia-related traits. In this study, we investigated both specific and shared serum metabolites associated with these two traits in 136 Caucasian women using a liquid chromatography-mass spectrometry method. A joint analysis of multivariate traits was used to examine the associations of individual metabolites with muscle mass measured by the body mass index-adjusted appendicular lean mass (ALM/BMI) and muscle strength measured by hand grip strength (HGS). After adjusting for multiple testing, nine metabolites including two amino acids (aspartic acid and glutamic acid) and an amino acid derive (pipecolic acid), one peptide (phenylalanyl-threonine), one carbohydrate (methyl beta-D-glucopyranoside), and four lipids (12S-HETRE, arachidonic acid, 12S-HETE, and glycerophosphocholine) were significant in the joint analysis. Of them, the two amino acids (aspartic acid and glutamic acid) and two lipids (12S-HETRE and 12S-HETE) were associated with both ALM/BMI and HGS, and the other five were only associated with ALM/BMI. The pathway analysis showed the amino acid metabolism pathways (aspartic acid and glutamic acid) might play important roles in the regulation of muscle mass and strength. In conclusion, our study identified novel metabolites associated with sarcopenia-related traits, suggesting novel metabolic pathways for muscle regulation.
2. New metabolic signature for Chagas disease reveals sex steroid perturbation in humans and mice
Makan Golizeh, John Nam, Eric Chatelain, Yves Jackson, Leanne B Ohlund, Asieh Rasoolizadeh, Fabio Vasquez Camargo, Louiza Mahrouche, Alexandra Furtos, Lekha Sleno, Momar Ndao Heliyon. 2022 Dec 15;8(12):e12380. doi: 10.1016/j.heliyon.2022.e12380. eCollection 2022 Dec.
The causative agent of Chagas disease (CD), Trypanosoma cruzi, claims thousands of lives each year. Current diagnostic tools are insufficient to ensure parasitological detection in chronically infected patients has been achieved. A host-derived metabolic signature able to distinguish CD patients from uninfected individuals and assess antiparasitic treatment efficiency is introduced. Serum samples were collected from chronic CD patients, prior to and three years after treatment, and subjected to untargeted metabolomics analysis against demographically matched CD-negative controls. Five metabolites were confirmed by high-resolution tandem mass spectrometry. Several database matches for sex steroids were significantly altered in CD patients. A murine experiment corroborated sex steroid perturbation in T. cruzi-infected mice, particularly in male animals. Proteomics analysis also found increased steroidogenesis in the testes of infected mice. Metabolic alterations identified in this study shed light on the pathogenesis and provide the basis for developing novel assays for the diagnosis and screening of CD patients.
3. Bacterial surface display library screening by target enzyme labeling: Identification of new human cathepsin G inhibitors
Joachim Jose, Dirk Betscheider, Dirk Zangen Anal Biochem. 2005 Nov 15;346(2):258-67. doi: 10.1016/j.ab.2005.08.019. Epub 2005 Sep 1.
The aim of this study was to establish a new tool for screening surface displayed peptide libraries based on the idea that cells expressing an enzyme inhibitor at the surface can be specifically labeled by the target enzyme. For this purpose peptide P15, exhibiting a K(i) value of 0.25 microM toward human cathepsin G, was expressed on the Escherichia coli cell surface by the use of Autodisplay. Purified cathepsin G was coupled to biotin and incubated with cells expressing the inhibitor. After addition of streptavidin-fluorescein isothiocyanate, these cells could be clearly differentiated from control cells by whole-cell fluorescence using flow cytometer analysis. To determine whether this protocol can be used for the sorting of single cells, a mixed population of cells with and without inhibitor was treated accordingly. Single cells were selected by increased fluorescence and sorted using fluorescence-activated cell sorting (FACS). Single cell clones were obtained and subjected to DNA sequence analysis. It turned out that the bacteria selected by this protocol displayed the correct peptide inhibitor at the cell surface. The protocol was then used to screen random peptide libraries, expressed at the cell surface, and a new lead structure for human cathepsin G (IC50 = 11.7 microM) was identified. The new drug discovery tool presented here consists of three steps: (a) surface display of peptide libraries, (b) selection of single cells with inhibiting structures by using the inherent affinity of the target enzyme, and (c) sorting of single cells, which were labeled by FACS.
Recommended Products
| BBF-01693 | Doxorubicin EP Impurity A (Daunorubicin) | Inquiry |
| BBF-01825 | Loganin | Inquiry |
| BBF-02642 | Lactonamycin | Inquiry |
| BBF-02614 | Nystatin | Inquiry |
| BBF-03753 | Baicalin | Inquiry |
| BBF-00677 | 3-Amino-3-deoxy-D-glucose | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
